 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 06/04/2003 | | | | European Clinical Trial Shows Nymox NicAlert™ Product Can Help Smokers Quit
topic: Tobacco Exposure Tests
June 4, 2003: Nymox Pharmaceutical Corporation announced today that the results of a large clinical trial using the Company's NicAlert™ product in conjunction with nicotine replacement therapy (NRT) will be presented at the 12th World Conference on Tobacco or Health in Helsinki August 3-8, 2003. |
| 06/03/2003 | | | | Nymox Reports NXC-4720 E. Coli Product Update
topic: R&D: E coli and Other Antibacterial Treatments
June 3, 2003: Nymox Pharmaceutical Corporation announced today that NXC-4720 its product for E. coli O157:H7 meat contamination, has continued to make its milestones in product development. The product has been consistently validated in further independent tests. The Company will be extending its field trials. |
| 06/02/2003 | | | | Nymox Reports Positive New Data on AlzheimAlert™ Product
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
June 2, 2003: Nymox Pharmaceutical Corporation announced today that recent studies have shown that the Company's AlzheimAlert™ urine test is an accurate diagnostic aid for Alzheimer's disease (AD). |
| 05/29/2003 | | | | Recent Studies Support Statin Drug Treatment Potential in Alzheimer's Disease
topic: Statins and Alzheimer's Disease
May 29, 2003: The major potential importance of statin drugs in Alzheimer's disease (AD) was bolstered by studies presented at the Fourth Manhattan Alzheimer's Disease Conference in New York on May 27. At the meeting, Dr. Larry Sparks of the Roberts Laboratory for Neurodegenerative Disease presented data from extensive studies supporting the underlying mechanism for the potential value of statins in the treatment of AD. |
| 05/27/2003 | | | | Nymox Scientists Uncover Major New Molecular Clue to Alzheimer's Disease
topic: R&D: Spherons and Alzheimer's Disease
May 27, 2003: Scientists at Nymox Pharmaceutical Corporation have uncovered a major new molecular clue to the mystery of Alzheimer's disease. In a presentation today at the 4th Manhattan Alzheimer's Disease Conference in New York City, it was reported that toxic amounts of a new substance referred to as "spherotoxin" were discovered in human brains. This spherotoxin material was found in the midst of areas believed by the scientists to trigger brain damage in Alzheimer's. |
| 05/23/2003 | | | | Swiss Study Shows Nymox's NicAlert™ Helps in Smoking Cessation Therapy
topic: Tobacco Exposure Tests
May 23, 2003: Nymox Pharmaceutical Corporation and Health4u (Basel, Switzerland) announced today that Nymox's NicAlert™ was successfully used in a double-blind, randomized, placebo-controlled trial for smoking reduction involving nictotine replacement therapy (NRT) for 170 patients at the Hirslanden Lung Center, Zurich, Switzerland. |
| 05/22/2003 | | | | Nymox's NicAlert™ Used in Conjunction With Nicotine Replacement Therapy Results in Higher Smoking Cessation Success Rates
topic: Tobacco Exposure Tests
May 22, 2003: Nymox Pharmaceutical Corporation's NicAlert™ is "easy to use, cost-effective and accurate," according to a team of Swiss researchers led by Dr. Karl Klingler of the Hirslanden Lung Center, Zurich, Switzerland. |
| 05/19/2003 | | | | Alzheimer's Disease Poses Major Challenge to Health Care System According to Experts
topic: R&D: Alzheimer's Disease Treatments
May 19, 2003: The challenges that Alzheimer's disease poses for health care systems as the baby-boom generation ages have been identified in expert reports and testimony before Congress. Nymox Pharmaceutical Corporation is targeting the diagnosis and treatment of Alzheimer's disease with new and exciting technologies and approaches according to Dr. Michael Munzar, Medical Director of Nymox. |
| 05/16/2003 | | | | Fourth Manhattan Alzheimer's Disease Conference, sponsored by Nymox Pharmaceutical Corp., to be Held in New York on May 27
topic: R&D: Alzheimer's Disease Treatments
May 16, 2003: Nymox Pharmaceutical Corporation will be sponsoring the Fourth Manhattan Alzheimer's Disease Conference in New York City on May 27, 2003. The Fourth Manhattan Alzheimer Disease Conference will feature world class experts and speakers on a broad range of medical, social, economic and legal issues surrounding the diagnosis, treatment, and care of Alzheimer's disease patients. |
| 05/15/2003 | | | | Nymox "Buy" Recommendation from Dutton & Associates
topic: Financial
May 15, 2003: Nymox Pharmaceutical Corporation announced today that J M Dutton & Associates have reiterated a "buy" recommendation for Nymox in a new Research Note. Dutton analyst Sherry Grisewood CFA issued the "buy" recommendation. |
|